Enovis (ENOV) Cash from Financing Activities (2010 - 2026)
Enovis (ENOV) posted quarterly Cash from Financing Activities of $26.0 million for Q2 2026, down 49.16% year-over-year from $51.2 million in Q2 2025, and up 135.69% quarter-over-quarter from -$72.9 million in Q4 2025.
Enovis (ENOV) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Enovis (ENOV) has reported Cash from Financing Activities for 17 consecutive years, with $26.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Financing Activities fell 49.16% year-over-year to $26.0 million; the TTM figure through Apr 2026 stood at -$77.6 million (down 331.74% YoY), while the FY2025 annual figure was -$52.4 million, down 106.19% from the prior year.
- Cash from Financing Activities improved to $26.0 million in Q2 2026 per ENOV's latest filing, from -$72.9 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $864.5 million in Q1 2024 and bottomed at -$495.5 million in Q3 2022.
- Historically, Cash from Financing Activities has averaged $28.4 million across 5 years, with a median of $2.5 million in 2024.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 3429.02% — and 2025, when it slumped 24837.16%.
- Enovis' Cash from Financing Activities stood at $41.6 million in 2022, then sank by 93.3% to $2.8 million in 2023, then sank by 819.97% to -$20.1 million in 2024, then tumbled by 263.12% to -$72.9 million in 2025, then soared by 135.69% to $26.0 million in 2026.
- Business Quant data shows ENOV's Cash from Financing Activities at $26.0 million in Q2 2026, -$72.9 million in Q4 2025, and -$36.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Enovis | 1.50 Bn | 1.49 Bn | 359.25 Mn | -50.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | -50.57 Mn |
| Jul 3, 2026 | -50.57 Mn |
| Apr 3, 2026 | 26.02 Mn |
| Apr 3, 2026 | 26.02 Mn |
| Dec 31, 2025 | -72.92 Mn |
| Dec 31, 2025 | -72.92 Mn |
| Oct 3, 2025 | -36.91 Mn |
| Oct 3, 2025 | -36.91 Mn |
| Jul 4, 2025 | 6.23 Mn |
| Jul 4, 2025 | 6.23 Mn |
| Apr 4, 2025 | 51.19 Mn |
| Apr 4, 2025 | 51.19 Mn |
| Dec 31, 2024 | -20.08 Mn |
| Dec 31, 2024 | -20.08 Mn |
| Sep 27, 2024 | -148,000.00 |
| Sep 27, 2024 | -148,000.00 |
| Jun 28, 2024 | 2.51 Mn |
| Jun 28, 2024 | 2.51 Mn |
| Mar 29, 2024 | 864.54 Mn |
| Mar 29, 2024 | 864.54 Mn |